综合放射治疗与免疫化疗用于不可切除的胆道癌症:一个探索性试点研究
Zhaohan Zhang1, Han Li1, Yuxuan Wang1
1Department of General Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China.
International journal of radiation oncology, biology, physics
|January 10, 2026
概括
将放射治疗添加到免疫疗法-化疗中,显著改善了无法切除的胆道癌症患者的存活率. 这种组合治疗可以提高整体存活率和无进展存活率,而不会增加严重的毒性.
科学领域:
- 在瘤学瘤学.
- 医学研究 医学研究
背景情况:
- 尽管目前的第一线免疫疗法-化疗,但不可切除的胆道癌 (BTC) 的存活率仍然很差.
- 放射治疗可能与免疫疗法和化疗协同作用,可能改善BTC患者的治疗结果.
研究的目的:
- 评估将放射治疗与免疫疗法-化疗相结合的疗效和安全性,与单独的免疫疗法-化疗相比,在不可切割的BTC中.
主要方法:
- 对497名无法切除的BTC患者进行了回顾性分析.
- 患者接受了放射治疗加免疫疗法-化疗 (RT+IO+CT) 或仅免疫疗法-化疗 (IO+CT).
- 倾向性得分匹配 (PSM) 用于创建可比的组来分析整体生存 (OS),无进展生存 (PFS) 和不良事件.
主要成果:
- 在PSM之后,每个组中有105名患者. 在RT+IO+CT组显著改善了OS (15.0 vs 9.0个月) 和PFS (10.0 vs 5.0个月).
- 放射治疗整合在肝脏内胆管癌 (ICC) 亚组中显示出明显的生存益处.
- 两组之间没有观察到严重治疗出现的不良事件 (TEAE) 的显著差异.
结论:
- 将放射治疗与免疫疗法-化疗相结合,显著改善了不可切割的BTC的生存结果.
- 组合疗法耐受性良好,严重毒性没有增加.
- 通过随机对照试验进行进一步的确认是有必要的,以验证这些发现.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.9K
08:54Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
14.8K
相关概念视频
Cancer Therapies
8.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.6K
Targeted Cancer Therapies
7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.1K
Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Tumor Immunotherapy
2.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
